ArticleChemistryOpen2026
Synthesis, Characterization, and Biological Evaluation of Co(II), Cu(II), and Ni(II) Complexes With 2,2'-Bipyridine-5,5'-Dicarboxamide Ligands: Antibacterial and Enzyme Inhibition Studies.
Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study reports the synthesis and characterization of two novel 2,2'-bipyridine-5,5'-dicarboxamide ligands (L1 and L2) and their corresponding Co(II), Cu(II), and Ni(II) complexes. The structures of the free ligands were verified using FTIR, NMR, UV-Vis, elemental analysis, and mass spectrometry, while the metal complexes were characterized through FTIR, MALDI-TOF MS, UV-Vis, and magnetic susceptibility techniques. Single-crystal X-ray diffraction was employed to elucidate the structure of L1. Biological evaluation against resistant bacterial strains identified Co-L2 as a potent antimicrobial agent, exhibiting a quantitative Minimum inhibitory concentration (MIC) of 500 μg/mL against E. coli, P. aeruginosa, and S. aureus. Furthermore, enzyme inhibition assays revealed that Ni-L2 was the most effective inhibitor for pancreatic lipase (IC50 = 0.36 μM) and butyrylcholinesterase (IC50 = 4.53 μM). In contrast, the free L2 ligand demonstrated the strongest inhibitory potency against acetylcholinesterase (IC50 = 0.479 μM). These findings underscore the influence of 5,5'-regiochemistry on the biological efficacy of bipyridine-based systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.